BY CLAUDE SOLNIK

A clinical trial found that a new system can more accurately show correlation between improvement and worsening of prostate cancer, according to the company.

A Stony Brook-based company says it has developed a system that in a  clinical  trial correlated more closely to identifying prostate cancer’s development and defeat than PSA tests.

LineaRx said its system in a Phase II trial seeking recurrent prostate cancer demonstrates “the number of circulating tumor cells correlates more directly” with the status of the disease.

LineaRx, Inc., a subsidiary of  Applied DNA Sciences, Inc, said its platform demonstrated “superior correlation over Prostate Specific Antigen or PSA” in an ongoing Phase II trial in recurrent prostate cancer.

A test used in a clinical trial more directly correlates with prostate cancer progress and worsening than PSA, according to a Stony Brook-based company.

“The concentration of invasive circulating tumor cells or iCTCs identified per milliliter of whole blood correlated more directly with disease status than PSA levels,” the company said.

LineaRx Platform Used in Phase II trial in recurrent prostate cancer demonstrates the number of circulating tumor cells correlates more directly with disease status

STONY BROOK, N.Y., October 1, 2019 – LineaRx, Inc., the majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) focused on next-generation biotherapeutics, announced today that its invasive Circulating Tumor Cells (iCTCs) platform demonstrated superior correlation over Prostate Specific Antigen (PSA) in an ongoing Phase II trial in recurrent prostate cancer. Most notably, the concentration of rare iCTCs identified per milliliter of whole blood correlated more directly with disease status than did the levels of PSA. These iCTCs were captured and identified utilizing LineaRx’s technology platform recently acquired from Vitatex Inc.

LineaRx’s collaborator Tyme Technologies, Inc. (NASDAQ: TYME), reported yesterday results of this recently completed Phase II trial using SM-88 to treat recurrent prostate cancer at the Congress of the European Society of Medical Oncology (ESMO), one of the preeminent meetings for highlighting new cancer therapies and diagnostics. The study updated the safety and antitumor effects of SM-88 in men with non-castrate non-metastatic prostate cancer. Antitumor effects were assessed by post-therapy changes in PSA and the number of iCTCs. Results showed that patients treated with this oral non-hormonal therapy maintained metastases-free survival without testosterone deprivation or typical hormonal therapy side effects.

Dr. Wen-Tien Chen, Principal Investigator of CTC Programs at LineaRx stated: “This use of iCTC quantification for providing earlier and more accurate identification of prostate cancer shows the importance of running trials using the iCTC functional capture and identification system from LineaRx. Published studies have shown that the concentration of iCTCs in blood correlates with disease status across other hard tumors, including metastatic sarcoma, pancreatic, ovarian, breast, lung and colorectal cancers.  We believe our proprietary platform can help diagnose these difficult cancers earlier and with superior predictive capability.”

The current reported SM-88 Phase II study examines iCTCs in prostate cancer for what we believe is the first time in a clinical trial. While PSA has historically been the recognized biomarker for prostate cancer, many studies over the last 20 years have shown it is an inadequate biomarker, since it may become elevated in patients with no apparent disease, or less serious pathology than cancer. Intensive efforts have been directed towards alternative prostate cancer biomarkers, particularly those that can predict disease aggressiveness and help to drive better treatment decisions. However, biomarker research has centered on disease diagnostics, rather than prognosis and prediction, which could work toward disease prevention—an important focus moving forward.

The authors concluded: “Reductions in iCTC number may be a more informative indicator of benefit than changes in PSA.”  Dr. Chen added, “New prostate cancer biomarkers should be targeted to addressing unmet clinical needs in prostate cancer management, including indicators for disease with low PSA values (<10ng/mL), prognostic markers to distinguish indolent from aggressive disease, and biomarkers for metastatic cancer.”

LineaRx’s iCTC technology is unique in that it isolates iCTCs on a functional basis (the invasion of a model tissue for the extracellular matrix, or the tissue between cells in an organ) and allows the cells to be cultured for deeper genomic analysis. iCTCs are a model for metastasis, since the tumor cells have left the primary tumor and entered the circulation. The LineaRx platform may serve as a standalone device or as a front-end to increase the sensitivity of approved diagnostics.

”iCTCs have the potential for metastasis, and may be very useful in the diagnosis of cancer, even before tumors may be imaged,” said Dr. James Hayward, CEO of LineaRx. “The present study is exciting because we believe it shows that iCTCs may be used to accurately follow therapy success in this very prevalent cancer while also providing new tools for cell and gene therapy design and production.”

About Tyme Technologies, Inc
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, Tyme Technologies, Inc.’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. For more information, visit www.tymeinc.com. Follow Tyme Technologies, Inc.  on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.

About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria. Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture. Go to www.adnas.com for more information on LineaRx and to learn more about how Applied DNA makes life real and safe. LineaRx is a majority-owned Applied DNA Sciences, Inc. (Nasdaq: APDN) company.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the risk that the acquisition will not be successfully integrated with LineaRx or that the potential benefits of the acquisition will not be realized, the Company’s  history of net losses, limited financial resources, limited market acceptance , the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, uncertainties relating to its ability to maintain its NASDAQ listing in light of delisting notices received and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019,May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com
web: www.adnas.com, www.linearxdna.com
twitter: @APDN, @LineaRxDNA

GHCL’s strengths revolve around its penchant for innovation and consistent product development with its aim of becoming highly competitive, backed as it is with its strong passion for sustainability, thought leadership in creating intellectual property and its ability to partner with multiple agencies to make its popular strategy a success. The key weakness at this point of time is the limited breadth of its product basket and lack of diversification within the realm of Home Textiles.

GHCL has taken a very clear leadership position on sustainability across global home furnishing manufacturers. In the previous year, the company launched two unique bedding brands for sustainability – REKOOP by using recycled polyester from post-consumer PET bottles, with forensic tagging by Applied DNA Sciences to secure traceability across the supply chain, and CIRKULARITY, a brand that supports the Circular Economy and focuses on the 3 Rs – Reduce, Reuse and Recycle.

By Chris Remington

STONY BROOK – Molecular technologies specialist Applied DNA Sciences (ADNAS) has received an order of US $1 million to supply its SigNature T tagging technology for the 2019/20 cotton ginning season which begins in October.

The Company’s SigNature T technology, paired with its genotyping and digital systems, will be utilised to tag, test and track the Pima variety of cotton – sold by the brand PimaCott – over the coming months in San Joaquin Valley, California.

SigNature T taggant and its genotyping and IT complements offer traceability and identity for cotton throughout the supply chain

STONY BROOK, N.Y. September 24, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”, the “Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today that it received a $1 million order to supply SigNature^® T taggant for cotton in the upcoming 2019 – 2020 ginning season which begins in October. The Company’s SigNature T technology, paired with its genotyping and digital systems, will be used to tag, test and track the Pima cotton variety grown in the San Joaquin Valley, California that is sold under the PimaCott^® brand nationwide and online by the largest home goods retailer in the U.S.

“We are pleased that the value of forensic traceability and genotyping for cotton continues to translate to recurring demand for tagged cotton across the home textile category,” said Dr. James A. Hayward, president and CEO of Applied DNA. “We believe the SigNature T taggant platform, combined with our partner’s high standards in supply chain quality practices, assure them brand protection and label-claim compliance for retailers and consumers.”

The SigNature T taggant system utilizes fully-automated DNA Transfer Systems in the “Industrial Internet of Things” design to ensure origin tagging process quality and as a basis for monitoring shipments, receipts and contract compliance. In addition to our Pima business, systems are installed in American Upland and Egyptian varietal cotton gins.  While the SigNature T analysis confirms the traceability mark, a patented fiberTyping^® analysis confirms cotton species from fiber to finished goods. Since 2014, and including the cotton tagged with this order, over 250 million pounds of cotton will have been tagged as the key to a total end-to-end traceability solution that is substantiated by forensic test data. Over 7,000 DNA tests have been conducted on cotton during the past five years.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and isolation of circulating tumor cells and the development of pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its ability to continue as a going concern, its history of net losses, limited financial resources, limited market acceptance, uncertainties relating to its ability to maintain its NASDAQ listing in light of delisting notices received and its recent hearing, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019 and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Program contacts: MeiLin Wan, Vice President Textile Sales, 631-240-8849, meilin.wan@adnas.com

By GREGORY ZELLER

Mark another impressive victory for LineaRX, this time in a two-front battle against cancer.

The Stony Brook-based biotech with innovation in its DNA (literally) has lent its unique DNA-sequencing technology to two vaccine-candidate tests run by Italian R&D company Takis Biotech, which is hot on the trail of new therapeutic cancer vaccines.

Tumor Reduction Demonstrated In Vivo Using Two Linear DNA Vaccines in Animal Models

STONY BROOK, N.Y., September 19, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its majority-owned subsidiary focused on next-generation biotherapeutics, and its collaborators Takis/Evvivax have completed pre-clinical animal studies of two vaccine candidates produced with linear DNA. Tests of both vaccines in mouse models demonstrated their ability to eliminate tumors in vivo, and to potentially prevent initial occurrence.

Evvivax S.R.L. designed a synthetic gene sequence to produce immunity in companion animals, directed against the protein telomerase (TERT), which is overexpressed in 85% of all mammalian cancers, whereas Takis S.R.L. designed a neoantigen-based cancer vaccine (TK), as a proof-of-concept of personalized immunology. For the studies, the TERT and TK based vaccines were produced in linear DNA form by LineaRx. Here is a summary of the recently completed studies performed in vivo:

• Previous results from Phase 1 of the collaboration’s Joint Development Agreement (JDA) confirmed immunogenicity in mice that were vaccinated with linear DNA against the human protein telomerase. The results reported herein are from the Phase 2 of the JDA using mice implanted with murine colon cancer.
• In the prophylactic use of the telomerase vaccine, wherein vaccination is done before addition of tumor cell lines to the mice, transplanted tumors were cleared within 10 days.
• In the therapeutic application using either TERT or TK linear DNA vaccine application, cancer cells were introduced and allowed to grow before administration of the vaccine. The successful reduction of total tumor mass was accomplished in conjunction with antibodies that targeted PD-1 and CTLA4. These antibodies, known as Checkpoint Inhibitors, are commonly used in oncology strategies that rely upon immunotherapy. In this setting the tumor cells were reduced significantly within 30 days.
• The strategy of the Takis TK neoantigen vaccine uses unique multiple-target antigenic epitopes that have been identified from the tumor of a human patient. The linear DNA can utilize the genes for several of the most effective universal antigens such as TERT, or neoantigens that are more personalized to the patient.

“We know that immune system has a key role in fighting cancer” said Dr. Luigi Aurisicchio, CEO of Takis/Evvivax. “Thanks to a deep knowledge of cancer immunobiology and cutting-edge vaccination technologies we have now the tools to provide new therapies to our pet friends and human patients.”

“Our unique triumvirate of JDA partners is compelling, in that clinical data accumulated from linear DNA vaccines for companion animals can be used to accelerate translation to human therapies by Evvivax and Takis” said Dr. James Hayward, president and CEO of Applied DNA and LineaRx. “Cancer vaccines would extend the lives of many family pets, and the benefit we believe would rapidly enure to humans.”

Linear DNA vaccines are being spearheaded by LineaRx to drive more efficient production methods and what are believed to be safer therapies for patients. Current production standards for human DNA vaccines use the circular DNA of plasmids that are grown in bacteria.  However, this raises concerns regarding the risk of integration of bacterial genes including the antibiotic-resistance genes into the human genome or transfer into commensal bacteria, that are a normal part of the human bacterial flora.

Dr Aurisicchio concluded, “The advantages of linear DNA should improve the safety and efficacy of all gene therapies, both in animals as well as humans.” The JDA partners expect to publish their results in the scientific literature soon and will initiate planned Phase 3 work in companion animals.

About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria. Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture. Go to www.adnas.com for more information on LineaRx and to learn more about how Applied DNA makes life real and safe. LineaRx is a majority-owned Applied DNA Sciences, Inc. (Nasdaq: APDN) company.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the risk that the acquisition will not be successfully integrated with LineaRx or that the potential benefits of the acquisition will not be realized, the Company’s  history of net losses, limited financial resources, limited market acceptance , the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, ability to maintain its NASDAQ listing in light of delisting notices received  and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019,May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

About Evvivax S.R.L. and Takis S.R.L
EVVIVAX, whose name is derived from Engineered Veterinary Vectored Immunotherapy and Vaccines, is a spin-off of Takis Biotech. EVVIVAX pursues the discovery and development of innovative Therapeutic Veterinary Cancer Vaccines based on viral vectors and DNA platform technologies. EVVIVAX frontline candidates are two therapeutic cancer vaccines for canine tumors: Tel-eVax and Erb-eVax. EVVIVAX aims at translating scientific breakthrough achievements in Cancer Immunotherapy into marketed innovative products in Veterinary and subsequently in Human Oncology.

Visit www.evvivax.com for more information.

Takis is a Biotech Company created by a group of scientists from Merck Research Laboratories (MRL). The group has more than 15 years of experience and an established track record in drug discovery in Oncology and is recognized for the conception and implementation of a number of innovative technologies. One of the main assets of Takis is the expertise in in vivo electro-gene-transfer, which can be used for a variety of clinically useful applications, from vaccine development to somatic gene therapy. Takis pipeline include four Cancer Vaccine candidates based on this technology. Takis is also actively involved in the generation of humanized monoclonal antibodies for use in Oncology and Infectious Diseases.

Visit www.takisbiotech.it for more information.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com

By Wayne Buchen

Recycled plastic, commonly referred to as rPET, continues to gain status as a highly desirable material used by textile, footwear and accessories manufacturers and consumers alike. The production of rPET requires 59 percent less energy compared to virgin polyester, and fibers made from recycled plastic offer the same high performance, durability and aesthetic. Additionally, rPET helps brands and manufacturers satisfy consumer demands and their sustainability goals.

PET is the acronym for the chemical substance polyethylene terephthalate, which is a strong, lightweight plastic in the polyester family. PET bottles and containers have been used to package beverage, food, personal care and household items since the 1970s.

But plastic is a tenacious substance that resists decomposition—it can live on in the environment for more than 500 years. More than 8 million tons of plastic end up in oceans each year, creating a daunting environmental problem. In fact, companies such as Shell are opening new PET facilities here in the U.S. to utilize the excess oil production that has become available because the country has built up such large reserves.

Brings Traceability to Industry Growing at 7.5% CAGR¹1; Navarpluma to Offer SigNature^® DNA to Manufacturing Customer Base

STONY BROOK, N.Y. September 5, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”, the “Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today a sales and marketing partnership with Navarpluma that extends Applied DNA’s Textiles business to include the global down and feather supply chain¹.

Formalization of the partnership between the two companies follows the completion of a groundbreaking technological advance by Applied DNA to utilize its SigNature^® DNA system to allow for traceability of materials in the down and feather industry. Navarpluma S.L., one of the world’s premier suppliers of down and feathers to the textile industry, will be the first to offer this new system to its customer base that counts some of the world’s most prestigious brands as clients.

“Use of Applied DNA’s SigNature DNA system gives Navarpluma the ability to validate the provenance of raw materials used. This ability conveys a significant competitive advantage to our products in the marketplace and to those products manufactured from our raw materials,” stated Benjamin Dix, Export Manager at Navarpluma. “We are very pleased to pioneer Applied DNA’s SigNature DNA system in our industry to establish a new gold standard for traceability that can be relied on by our clients and their customers.”

Tony Benson, Applied DNA’s managing director for EMEA, stated, “An industry leader, Navarpluma’s reputation in the market is that of an innovative and forward-thinking supplier known for employing new advances in technology to improve their products for their clients. Traceability has been a key goal for them over the past several years, and with their use of the SigNature DNA system – SigNature DNA forensic molecular tag together with hand-portable SigNify^® in-field testing equipment aggregated under our CertainT^® brand– enables an industry first: the full traceability of down and feathers. Being first-to-market with end-to-end traceability of its supply chain should attract new clients to Navarpluma while also creating stickier relationships with its customer base.”

This is Applied DNA’s first foray into the growing down feather market, which was valued at USD $5.9 Billion in 2017 and is expected to reach USD $10.25 Billion by the end of 2025, with a CAGR of 7.5% between 2017 and 2025[1].

About Navarpluma
In 2002 the French businessman Olivier Martin, with almost two decades of experience in the family feather and down business created by his forefathers in 1859, which he joined straight after finishing his International Business and Business Administration degree, decided to go it alone and take the helm of Navarpluma, a newly created company (2001).In 2004 Navarpluma built a new modern factory in Orcoyen, Northern Spain, allowing them to take an important technological and organizational leap forward, unique in the world of feather.

Working with the French company Ets Abel Crabos and with new state of the art facilities and the most advanced technology for down and feather production, Navarpluma are now able to market around 5,000 tons of the best feather and down material per year to clients around the globe.

[1] https://www.globenewswire.com/news-release/2018/03/27/1453318/0/en/Down-Feather-Market-to-Exceed-USD-10bn-and-growing-at-a-CAGR-of-7-5-between-2017-and-2025.html

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, uncertainties relating to its ability to maintain its NASDAQ listing in light of delisting notices received, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly report on Form 10-Q filed on August 13, 2019 and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Program contacts: Tony Benson, 44 (0) 7552 429341, tony.benson@adnas.com